Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.

Jeffrey S Damrauer Kyle R Roell Markia A SmithXuezheng SunErin L KirkKatherine A Hoadley Halei C BenefieldGopakumar IyerDavid B SolitMatthew I MilowskyWilliam Y KimMatthew E NielsenSara E WobkerGuido DalbagniHikmat A Al-AhmadieAndrew F OlshanBernard H BochnerHelena FurbergMelissa A TroesterEugene J Pietzak

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Assessment of the immune TME, rather than molecular subtypes, is a promising predictive biomarker of BCG response. Modulating the TME in an immunologically "cold" tumor warrants further investigation. Integrated transcriptomic and exome sequencing should improve treatment selection in NMIBC.

Keyphrases

muscle invasive bladder cancer
single cell
signaling pathway
rna seq
combination therapy
dna methylation
bioinformatics analysis
bacillus subtilis
replacement therapy